HC Wainwright Issues Optimistic Forecast for UNCY Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Research analysts at HC Wainwright increased their Q3 2025 earnings per share estimates for shares of Unicycive Therapeutics in a report issued on Wednesday, October 29th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.40) per share for the quarter, up from their prior forecast of ($0.51). HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q4 2025 earnings at $0.50 EPS, FY2025 earnings at ($0.47) EPS, Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.53) EPS, FY2026 earnings at ($1.89) EPS, FY2027 earnings at $2.23 EPS, FY2028 earnings at $5.04 EPS and FY2029 earnings at $7.61 EPS.

A number of other analysts have also recently commented on UNCY. Benchmark upped their price target on Unicycive Therapeutics to $21.00 and gave the company a “speculative buy” rating in a research note on Monday, September 15th. Wall Street Zen cut Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 25th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Unicycive Therapeutics in a research note on Thursday. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Unicycive Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.33.

Unicycive Therapeutics Price Performance

Shares of UNCY stock opened at $4.75 on Friday. The stock has a market cap of $83.89 million, a PE ratio of -1.15 and a beta of 1.86. The stock has a 50-day moving average of $4.42 and a 200-day moving average of $5.18. Unicycive Therapeutics has a one year low of $3.71 and a one year high of $11.00.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.18.

Institutional Trading of Unicycive Therapeutics

A number of large investors have recently bought and sold shares of UNCY. Lazard Asset Management LLC bought a new stake in Unicycive Therapeutics during the 2nd quarter worth approximately $55,000. JPMorgan Chase & Co. grew its stake in shares of Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after acquiring an additional 21,525 shares in the last quarter. Finally, Vivo Capital LLC grew its stake in shares of Unicycive Therapeutics by 14.0% during the 1st quarter. Vivo Capital LLC now owns 11,370,152 shares of the company’s stock worth $6,537,000 after acquiring an additional 1,400,000 shares in the last quarter. 40.42% of the stock is owned by institutional investors.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.